Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Evusheld

- PMLiVE

Kinarus’ KIN001 shows strong antiviral activity against BA.2 and BA.5 Omicron subvariants

The phase 2 trial of KIN001 in ambulatory COVID-19 patients is actively recruiting

- PMLiVE

AZ and MSD launch ‘Never Miss’ for prostate cancer awareness

Prostate cancer is often symptomless and is the second most common cancer in men globally

- PMLiVE

AstraZeneca to acquire Neogene Therapeutics in $320m deal

The agreement will build the company’s pipeline of cell-based cancer treatments

- PMLiVE

AstraZeneca and C4X Discovery sign exclusive $403m licensing deal

The collaboration aims to develop an oral therapy for inflammatory and respiratory diseases

- PMLiVE

Bristol Myers Squibb’s Opdivo recommended by NICE for rare gastroesophageal cancers

The PD-1 inhibitor demonstrated a statistically significant benefit in overall survival

Can Cinderella save us?

UK government launches consultation on silent AMR pandemic

The consultation will call upon the latest data from experts on antimicrobial resistance

- PMLiVE

Takeda’s Exkivity receives NICE recommendation for rare form of lung cancer

Patients with EGFR Exon20ins+ NSCLC make up approximately 2% of NSCLC cases

- PMLiVE

Moderna’s bivalent Omicron-targeting boosters show superiority to original COVID-19 vaccine

Both boosters produced a better immune response against Omicron BA.4/BA.5 subvariants

- PMLiVE

NICE publishes draft guidance recommending three COVID-19 treatments

Five treatments have not been recommended for use, with the organisation citing cost-effectiveness concerns

- PMLiVE

WHO, WIPO and WTO to hold technical symposium on pandemic preparedness

The event will examine ways to build resilience to be better prepared for future pandemics

- PMLiVE

AstraZeneca receives CHMP recommendations for Imfinzi, Enhertu and Lynparza

The treatments are for use in prostate, biliary tract and advanced gastric cancer

- PMLiVE

CDC shows new BQ.1 and BQ 1.1 Omicron subvariants account for 44% of US COVID-19 cases

The two new variants accounted for over 32% of US cases the prior week

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links